Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This updated edition is a great reference for anyone working in multinational product development and marketing.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 23 May 2017 | By Zachary Brennan
The European Medicines Agency (EMA) on Tuesday opened for public consultation a draft guideline on serious breaches of clinical trial regulations or clinical trial protocols.
The agency says the guideline is intended to "outline the practical arrangements for notification of serious breaches … provide advice on what should and what should not be classified as a serious breach and what must be reported … [and] To outline possible actions that may be taken by the EU/EEA Member States concerned (MSC) in response to notifications of serious breaches."
The draft says that within seven calendar days, the sponsor or anyone that has a contractual agreement with the sponsor (including contract research organizations, co-development partners, etc.) and is aware of the breach must report it.
And though the majority of deviations from clinical trial protocols and good clinical practice (GCP) "are technical deviations that do not result in harm to the trial subjects or significantly affect the scientific value of the reported results," EMA says the judgment on the significance of the breach "depends on a variety of factors, for example: the design of the trial, the type and extent of the data affected by the breach, the overall contribution of the affected data to key analysis parameters, the impact of excluding the data from the analysis etc."
EMA adds: "It is the responsibility of the sponsor to thoroughly perform a root cause analysis to identify the cause of the serious breach and to assess the impact of the breach on the scientific value of the trial as well as the impact on the subject’s safety and rights."
The agency also offers the example of a breach that leads to the removal of data from the overall analysis, which it says does not negate the fact that a breach has occurred and "should be treated according to the legal requirements. In the same way, if one or more overdose(s) occurred due to a miscalculation, this would still meet the criteria for a serious breach regardless of whether or not the subject(s) suffered adverse reactions as a result of that overdose."
An appendix in the draft guideline also features other examples of serious breaches.
Draft guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
Tags: clinical trial regulations, EMA guideline
Regulatory Focus newsletters
All the biggest regulatory news and happenings.